drugset / Trial / NCT03691818

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

NCT03691818

Phase 2 Completed 353 enrolled Tianjin XinChen-Techfields Pharma Co., LTD.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a randomized, double-blind clinical trial in a Chinese population.

Timeline

Start
2018-07-16
Primary completion
2019-10-21
Completion
2019-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject IBUPROFEN TRELAMINE Small molecule 1 unknown Topical
Subject IBUPROFEN TRELAMINE Small molecule 2 unknown Topical
Subject IBUPROFEN TRELAMINE Small molecule 4 unknown Topical
Comparator Ibuprofen Small molecule 400 mg Oral

Indications